Navigation Links
Patent Issued In China For EntreMed's Lead Drug Candidate ENMD-2076
Date:5/6/2013

dministration (CFDA) for ENMD-2076 to conduct global clinical trials in triple-negative breast cancer patients. 

About EntreMed

EntreMed is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer.  EntreMed is currently conducting a Phase 2 study of ENMD-2076 in triple-negative breast cancer and a Phase 2 study of ENMD-2076 in advanced/metastatic soft tissue sarcoma.  The Company is headquartered in Rockville, Maryland and has local operations in Beijing, China.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.  Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.  ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers.  ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma, and is currently completing a Phase 2 trial for ovarian cancer.  EntreMed is currently conducting a dual-institutional
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
2. Patent Issued In U.S. For EntreMeds 2ME2 In Rheumatoid Diseases
3. Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series
4. Dr. Isaac Eliaz Awarded Patent for Modified Citrus Pectin and Alginates
5. Absorption Pharmaceuticals to Receive Patent for Premature Ejaculation Topical Medication
6. LamdaGen Corporation Issued United States Patent for Diagnostics on Plasmonic-Based Nanosensors
7. Fuisz Pharma Announces Intent to Divest Strategic Patent for Detection of Opioid Abuse; Seeks Offers for Patent through May 2013
8. Bioinformatics Market: Technologies, Patenting Trends & 2017 Forecasts
9. Neuralstem Receives Notice Of Allowance Of Patent Covering Use Of Stem Cells To Treat Amyotrophic Lateral Sclerosis
10. VolitionRx Files Two Patent Applications
11. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015  Mobility Ventures LLC, an AM ... Bank of America (NYSE: BAC ) that ... financing of the revolutionary MV-1 - - the world,s ... ground up to provide safe and comfortable transportation for ... their loan to purchase a new MV-1 vehicle at ...
(Date:2/26/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/2vn6hh/radiation_therapy ... Therapy Equipment - Global Strategic Business Report" report ... the worldwide markets for Radiation Therapy Equipment in US$ ... Planning Systems, and Radiation Therapy Simulator. The report provides ... , Japan , ...
(Date:2/26/2015)... ASHKELON, Israel , Feb. 26, 2015 ... developer of the GlucoTrack ® model DF-F, a ... Dr. Lutz Heinemann , Ph.D., will head its ... key opinion leaders in the field of Diabetes research, ... Heinemann , Ph.D has been Chief Executive Officer and ...
Breaking Medicine Technology:Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3Radiation Therapy Equipment - Global Strategic Business Report 2015-2020: Linear Accelerator, Treatment Planning Systems, and Radiation Therapy Simulator 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 3Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 4
... Oct. 11 ECRI Institute® ( www.ecri.org ), an ... improving patient care, is pleased to announce Kaiser Permanente ... health plan,  as the winner of the 5th annual ... health technology management. The Health Devices Achievement Award ...
... N.C., Oct. 11 Talecris Biotherapeutics Holdings Corp. (Nasdaq: ... release before the market opens on October 28, 2010. Due ... be hosting a conference call to discuss its third quarter ... Inspiration. Dedication. Innovation. Talecris Biotherapeutics is ...
Cached Medicine Technology:ECRI Institute Names Kaiser Permanente Winner of 5th Annual Health Devices Achievement Award 2ECRI Institute Names Kaiser Permanente Winner of 5th Annual Health Devices Achievement Award 3
(Date:2/26/2015)... When Cosmetic Town launched in 2012, its Board ... will soon be, the cornerstone of work that bolsters ... insight that will be accessible to the public, will ... maintained during its existence. Users have more data to ... visiting the Cosmetic Town Journal’s doctor’s page. There the ...
(Date:2/26/2015)... CA (PRWEB) February 26, 2015 ... wound center management, recently expanded its executive team by ... care industry experience. At the same time two WCA ... company. Wound Care Advantage (WCA) was founded in 2002 ... companies still operating today. The WCA team believes that ...
(Date:2/26/2015)... Somerset, NJ (PRWEB) February 26, 2015 ... global provider of advanced delivery technologies and ... health products, has today announced several expanded ... network. The expansions have been implemented in ... clinical packaging, where the proportion of highly-potent ...
(Date:2/26/2015)... 26, 2015 The Reproductive Science Center ... newly renovated office in Lawrenceville, NJ. , ... of New Jersey’s physicians, and NJ Top Docs, have ... in the areas of infertility and reproductive medicine. This ... success rates and providing current, high quality medical treatments ...
(Date:2/26/2015)... Ann Arbor, Michigan (PRWEB) February 26, 2015 ... two different procedures that accomplish two different things—but they ... procedure. When blending a tummy tuck with liposuction, Michigan’s ... LipoTuck ,” which he's seen grow in popularity by ... practice. , Why are more patients seeking to combine ...
Breaking Medicine News(10 mins):Health News:Cosmetic Town has now Recreated Itself by Adding New Features 2Health News:Wound Center Management Leader WCA Expands Its Team to Include Additional Industry Experts 2Health News:Wound Center Management Leader WCA Expands Its Team to Include Additional Industry Experts 3Health News:Wound Center Management Leader WCA Expands Its Team to Include Additional Industry Experts 4Health News:Catalent Expands European Clinical Packaging Capabilities, Highlighting Growing Industry Need for Specialty Handling 2Health News:Catalent Expands European Clinical Packaging Capabilities, Highlighting Growing Industry Need for Specialty Handling 3Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 2Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 3Health News:Dr. Pramit Malhotra Reports a Rise in Patients Combining Liposuction and Tummy Tuck in Michigan, Citing the “Power LipoTuck” 2Health News:Dr. Pramit Malhotra Reports a Rise in Patients Combining Liposuction and Tummy Tuck in Michigan, Citing the “Power LipoTuck” 3
... “black box warning” to three asthma drugs//, Foradil, ... the manufacturers that the drug should carry clearly ... ,Adavir and Serevent are manufactured by ... the drug Foradil which contains a different long-acting ...
... for all chocolate lovers, as against the general thought ... that dark chocolate can actually improve heart function. ... dark chocolate consumption on blood vessel function in 17 ... these subjects exhibited a 7 % decrease in aortic ...
... People suffering from irritable bowel syndrome may be having ... bowel syndrome is one of the most common gastrointestinal ... abdominal pain and changed bowel habits with no particular ... for the condition. ,Scientists from St. George's ...
... early breast cancer// patients increased the risk of ... study published in Journal of clinical oncology reports ... higher than standard cumulative doses of epirubicin and ... myeloid leukemia (AML) or Myelodysplastic syndrome (MDS). ...
... believe it but science is skeptical about it.// However there ... healing. ,Some scientists also now are starting to ... others, influence our health. ,The new age healing mantra ... approach to wellness”, which unites the science of medicine with ...
... from injuries. However at times due to age or ... Researchers have identified a molecule that when is deficient, ... from University of Illinois-Chicago had reported in their findings ... and this may be targeted to treatment in cases ...
Cached Medicine News:Health News:FDA gives “black box warning” against three asthma dru 2Health News:High-Dosage of Epirubicin and Cyclophosphamide may cause AML 2Health News:Link between Faith, Health and Healing 2Health News:Link between Faith, Health and Healing 3
Performa cemented stem....
Porous foundation 470 series....
The AcuMatch M-Series modular femoral stem is a unique, innovative three-piece modular stem designed to address even the most complicated of clinical indications....
The link classic plus hip stem for cemented primary hip replacement surgery...
Medicine Products: